Breakout Bulletin: July 13-July 17

You’re busy. Between patients, prior authorizations, inbox messages, and everything else on your plate, keeping up with the literature is the first thing that slips. Dermatology Times NP/PA Connect is here to make sure it doesn’t. Each week, we pull the most clinically relevant news from across dermatology and bring it straight to your inbox — what’s new, what it means, and what’s worth watching. This week: a phase 2a antibody keeps working on alopecia areata even in patients who've already failed a JAK inhibitor, a vitiligo roundtable exposes how insurance denials rather than evidence are steering treatment choice, a simple blood test flags which urticaria cases will drag on longest, and a sunscreen pioneer explains why the message still isn't landing for patients with skin of color.

Bempikibart Keeps Working on Alopecia Areata Even After JAK Inhibitors Don't

Q32 Bio has reported positive 36-week topline results from part B of the SIGNAL-AA phase 2a trial of bempikibart, a fully human anti-IL-7Rα antibody, in patients with severe or very severe alopecia areata (AA).¹ In the modified intent-to-treat (mITT) population, bempikibart produced a mean 35.3% reduction in Severity of Alopecia Tool (SALT) score from baseline, with a SALT20 response (80% scalp coverage) in 40.0% of mITT patients and 30.3% of the intent-to-treat group. SALT30 and SALT50 responses reached 44.0% (mITT) and 33.3% (ITT).¹

Of the 33 patients enrolled, 36.4% had previously failed an oral JAK inhibitor—which is where these findings become especially interesting for NPs and PAs managing refractory disease. Safety was favorable, with no serious adverse events or grade 3 or higher treatment-related events reported. Injection-site reactions occurred in 36.3% of patients and were described as mild and largely self-limited.¹ Bempikibart currently holds FDA Fast Track designation, and Q32 Bio plans to begin a registration-directed program during the first half of 2027.²

The robust efficacy data in a population that includes JAK inhibitor-experienced patients, combined with a differentiated safety profile, demonstrate the potential for bempikibart to be a first-line treatment for alopecia areata. — Arash Mostaghimi, MD, MPA, MPH

MORE ON ALOPECIA AREATA

▶ Why it matters: For patients who've cycled through a JAK inhibitor without durable control, these encouraging phase 2a findings make bempikibart a pipeline therapy worth watching, not one ready to change practice just yet.

Insurance Barriers Continue to Shape Vitiligo Treatment Decisions

At a Dermatology Times Case-Based Roundtable in Nashville, Tennessee, clinicians working through three vitiligo cases repeatedly returned to the same obstacle: insurance coverage often dictated what patients could actually receive, regardless of the available evidence. Attendees described frequent denials when combining topical ruxolitinib with phototherapy because the combination is not specifically addressed in the product label, as well as continued challenges obtaining coverage for home phototherapy units when vitiligo is viewed as cosmetic rather than medically necessary.⁴

Evidence supporting conventional systemic immunosuppressants remains limited. In discussing a 29-year-old patient whose disease had progressed from stable arm involvement to facial lesions over 9 months, the panel weighed emerging oral JAK inhibitors such as povorcitinib and ritlecitinib against topical therapy, emphasizing that patient preference often becomes the deciding factor. The group also noted that visible-site disease, darker skin types, and greater body surface area are associated with a higher psychosocial burden, consistent with findings from the VALIANT survey.⁵

Methotrexate, mycophenolate, cyclosporine—the data's pretty poor actually for vitiligo. — Raj Chovatiya, MD, PhD, MSCI

MORE ON VITILIGO

▶ Why it matters: Build insurance appeals into the treatment plan from the first visit, and prepare patients for the timeline of repigmentation with topical ruxolitinib so they don't abandon therapy just before improvement begins.

Could Vitamin B12 Help Identify Patients With More Persistent CSU?

A cross-sectional study of 57 adults with chronic spontaneous urticaria (CSU) found that lower vitamin B12 levels were associated with significantly longer-lasting wheals.³ Patients with vitamin B12 deficiency (below 200 pg/mL), representing 15.7% of the cohort, had a median wheal duration of 120 minutes compared with 60 minutes among patients with normal vitamin B12 levels. Pruritus duration also trended longer in patients with deficiency, although the difference did not reach statistical significance. Vitamin B12 levels showed no association with overall urticaria activity score, angioedema, IgE levels, or autologous serum skin test positivity.

The authors proposed several biologically plausible mechanisms, including altered immune regulation, homocysteine-mediated inflammation, and mast cell activation. However, the study's small sample size, single-center design, and cross-sectional methodology mean the findings identify an association, not proof that correcting vitamin B12 deficiency improves CSU outcomes.

MORE ON CHRONIC SPONTANEOUS URTICARIA

▶ Why it matters: Consider checking a vitamin B12 level in patients whose wheals seem unusually persistent, but view a low result as one piece of the overall workup, not a treatment in itself.

The Sunscreen Message Still Isn't Reaching Patients With Skin of Color

Shontay Lundy, founder of Black Girl Sunscreen, told Dermatology Times that one of the most persistent misconceptions she encounters is the belief that darker skin doesn't require sunscreen because it doesn't burn. In reality, UV damage in melanated skin often presents differently, with patients noticing peeling or pigmentary changes rather than acute erythema after sun exposure.

Lundy also argued that sunscreen messaging has focused too narrowly on skin cancer prevention, overlooking concerns that often resonate more immediately with patients, including hyperpigmentation, uneven skin tone, and photoaging. She called for greater representation in dermatology research, education, and marketing, along with stronger collaboration between dermatologists and estheticians to reinforce consistent sun safety messaging.

Everybody needs to hold hands when it comes to the conversation of sun safety, sunscreen, and how to use it properly. It's bigger than a marketing story; your skin health is extremely important to your life. — Shontay Lundy

MORE ON SKIN OF COLOR DERMATOLOGY

▶ Why it matters: Broaden sunscreen conversations with patients of color beyond skin cancer prevention alone. Discuss photoaging, pigment preservation, and overall skin health, and don't assume visible sunburn is the sign patients are looking for.

Test Your Knowledge: This Week's Spot Test

This week's Dermatology Times Spot Test quizzes readers on recent developments surrounding Evommune's phase 2b chronic spontaneous urticaria program, including EVO756's mechanism of action, trial results, and study design.

ALL SPOT TESTS

▶ Why it matters: It takes just a few minutes to reinforce this week's biggest clinical headlines, and see how much of the latest dermatology news you've retained.

References

1. Q32 Bio. Q32 Bio announces positive 36-week topline results from part B of the SIGNAL-AA phase 2a clinical trial of bempikibart in alopecia areata. News release. July 13, 2026. Accessed July 13, 2026. https://ir.q32bio.com/news-releases/news-release-details/q32-bio-announces-positive-36-week-topline-results-part-b-signal
2. Q32 Bio. Q32 Bio announces FDA Fast Track designation granted to bempikibart (ADX-914) for the treatment of alopecia areata. News release. April 30, 2025. Accessed July 13, 2026. https://ir.q32bio.com/news-releases/news-release-details/q32-bio-announces-fda-fast-track-designation-granted-bempikibart/
3. Mali KR, Konda D, Thota SS, et al. Evaluation of vitamin B12 levels in chronic spontaneous urticaria patients and correlation with severity of disease. Maedica (Bucur). 2026;21(2):406-413. doi:10.26574/maedica.2026.21.2.406.
4. Chovatiya R. Vitiligo in practice: case-based approaches for patient care. Presented at: Dermatology Times Case-Based Roundtable; June 18, 2026; Nashville, TN.
5. Ezzedine K, Parsad D, Harris JE, et al. Depression and depressive symptoms among people living with vitiligo: findings from the cross-sectional, population-based global VALIANT survey. J Dermatolog Treat. 2025;36(1):2504082. doi:10.1080/09546634.2025.2504082.

Dermatology Times NP/PA Connect | The Breakout Bulletin